Biotie Therapies - Company Announcement

Change in the number of votes relating to Biotie Therapies Corp.'s shares

Biotie Therapies Corp.          Stock Exchange Release        6 June 2011 at
9.00 a.m.

Change in the number of votes relating to Biotie Therapies Corp.'s shares

The Swiss subsidiary of Biotie Therapies Corp. ("Biotie" or the "Company"),
Biotie Therapies Holding AG (previously Synosia Therapeutics Holding AG) has
conveyed a total of 2,132,860 Biotie shares against consideration pursuant to
the option programs. The conveyed shares previously held by the Company's
subsidiary have not carried any voting rights. As a result of the conveyances,
the total number of votes attached to Biotie's shares increased by 2,132,860
votes to 374,814,962 votes. The conveyance does not affect the number of
registered shares (total of 387,594,457 shares) but the number of the Company's
shares held by the Biotie Therapies group is reduced to 12,779,495 shares. The
parent company Biotie does not own any treasury shares.

The conveyance of Biotie shares relates to the option plan of Synosia
Therapeutics Holding AG (currently Biotie Therapies Holding AG, "Synosia")
acquired by Biotie in February 2011. According to such Synosia share option
plan, options have been granted to employees, former directors and consultants.
In connection with the completion of the acquisition of Synosia, the option plan
was amended so that instead of shares in Synosia an aggregate maximum of
14,912,155 shares in Biotie may be subscribed based on the plan. Biotie issued
these 14,912,155 shares to its current subsidiary Synosia in connection with the
acquisition to be further conveyed to the option holders when they potentially
exercise their option rights in accordance with the terms and conditions of the
option program.

After these conveyances, the total number of shares which can be subscribed by
virtue of the Synosia option plans amounts to 12,779,495, which represents 3.3%
of the total amount of shares in the Company.

Turku, 6 June 2011

Biotie Therapies Corp.

Timo Veromaa
President and CEO

For further information, please contact:

Virve Nurmi, Biotie Therapies Corp.
tel. +358 2 274 8900
e-mail: virve.nurmi@biotie.com

DISTRIBUTION
NASDAQ OMX Helsinki Ltd
Main Media
www.biotie.com


[HUG#1521264]